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CASE REPORTUse of clamping to enhance intralesional bleomycin
therapy for nodular basal cell carcinoma
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egional chemotherapy usually involves using
intra-arterial or intracavitary drug infusion
to increase drug concentration within
tumor-containing tissue while minimizing systemic
toxicity.1 It has long been used as a treatment
modality for various malignancies including
melanoma, soft tissue sarcoma, and primary brain
tumors.1 Analogous to regional chemotherapy,
intralesional chemotherapy has been used to maxi-
mize drug concentrations within tumor-containing
cutaneous tissues for the treatment of basal cell
carcinoma. However, intralesional chemothera-
peutic agents usually require multiple injections
over time to achieve histologic clearance of basal
cell carcinoma. For example, 9 to 10 injections of
interferon alfa-2b and 6 injections of sustained-
release 5-fluorouracil were used to achieve histologic
cure rates of 67% to 86%2 and 91%,3 respectively.
Electroporation has been used to increase the
efficacy of intralesional bleomycin therapy so that a
single injection can result in a 94% clearance rate of
basal cell carcinoma.4 However, electrochemo-
therapy requires expensive equipment that may not
be accessible to most physicians. A more practical
method of reducing the number of injections
required to achieve therapeutic cytotoxicity is to
increase the duration of exposure to chemotherapy
by mechanically isolating the area around the basal
cell carcinoma.CASE REPORT
A 69-year-old white man presented to our derma-
tology clinic with a 1-year history of an asymptomatic
8-mm 3 8-mm papule on his left ear lobe. The
diagnosis of nodular basal cell carcinoma was made
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refused surgical therapy, so we decided to treat the
basal cell carcinomawith intralesional bleomycin. To
minimize the number of injections and amount of
bleomycin injected, a chalazion clamp was used to
isolate the tissue surrounding the basal cell
carcinoma. One unit (1.0 mL x 1 U/mL) of bleomycin
in 1% lidocaine with 1:100,000 epinephrine was
injected into the clamped basal cell carcinoma
entering the clamped area between the 2 sides of
the clamp to prevent leakage. The injected
bleomycin remained within the clamped area as
evidenced by a localized raised and stretched area of
skin (Fig 1, A). After 20 minutes, an 18-gauge needle
was used to remove most of the injected fluid from
clamped area and the chalazion clampwas removed.
Aside from minor discomfort, no other adverse
effects were observed or reported by the patient.
One year after treatment, the basal cell carcinoma
appeared clinically cured (Fig 1, B). The clinical
result was confirmed by step sections from a 4-mm
punch biopsy.DISCUSSION
In this case, a chalazion clamp was used to
enhance the efficacy of intralesional bleomycin
therapy for a nodular basal cell carcinoma in a
patient who refused surgery. The clamp isolated
the area around the basal cell carcinoma to increase
the concentration of bleomycin to which the tumor
cells were exposed. The increased duration of
exposure to the lidocaine may have also enhanced
bleomycin’s cytotoxic effects through interaction
with tumor cell membranes.5 We also suspect that
stretching of the skin caused by injecting bleomycin
into a confined area may have increased cellular1 Riverside Circle Suite 300, Roanoke, VA 24016. E-mail:
mskolodney@carilionclinic.org.
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Fig 1. A, Nodular basal cell carcinoma on the left ear mechanically isolated with a chalazion
clamp during intralesional bleomycin therapy. B, One year after treatment.
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drug. Furthermore, by isolating the area around the
basal cell carcinoma, therapeutic cytotoxicity could
be achieved with a relatively low total dose of
bleomycin, and most of the injected chemo-
therapeutic drug could be removed after the
treatment. Thus, there was a reduced risk of
potential systemic side effects, such as flagellate
hyperpigmentation,6 from the intralesional bleo-
mycin. The use of the chalazion clamp ultimately
enabled a single dose of 1.0 U of bleomycin to result
in a histologic cure of the patient’s nodular basal cell
carcinoma.
There are potential limitations to this case. The
choice of the 20-minute treatment duration was
somewhat arbitrary, as there are no studies of
intralesional bleomycin therapy with mechanical
isolation to suggest the duration of chemotherapy
exposure necessary to achieve tumor cytotoxicity
without permanent damage to normal tissues. It is
possible that an interval less than 20 minutes could
achieve tumor cytotoxicity. However, as the duration
is increased, there is an increased risk of damage to
normal tissue. Studies are needed to determine
the optimal duration of mechanically isolated
intralesional bleomycin therapy.
Another potential limitation is the possibility that
the pretreatment shave biopsy removed the tumor.
This is unlikely given only part of the tumor area was
shaved, and visible tumor was present at the time ofthe intralesional therapy. It should also be noted that
the chalazion clamp technique is limited to areas of
skin that permit clamping, such as the ear. However,
it is possible that other methods of mechanical
isolation could provide similar therapeutic
enhancement in areas that cannot be isolated by a
chalazion clamp. Despite potential limitations, this
case suggests that mechanical isolation may be a
practical, inexpensive method for enhancing the
efficacy of intralesional bleomycin for patients
with nodular basal cell carcinoma who desire a
nonsurgical therapy.
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